Cirrus Therapeutics secured funding and established a research collaboration with Singapore Eye Research Institute to advance ocular immunology therapies, including an IRAK-M targeting gene therapy and retinal pigment epithelium cell therapy for geographic atrophy. The partnership accelerates preclinical development and positions the company in the expanding ocular immunology sector.
Key Points
- IRAK-M gene therapy targets immune dysfunction in eye disease
- RPE cell therapy addresses geographic atrophy progression
- Singapore partnership expands translational research capacity
Longevity Analysis
Geographic atrophy represents a primary driver of vision loss in aging populations, with immune dysregulation as a central mechanism. The approach of modulating immune signaling in retinal tissue addresses a root cause rather than symptomatic management. As the eye's defense and regeneration systems deteriorate with age, targeted interventions that restore immune homeostasis and support epithelial cell function offer potential to slow or arrest functional decline in a tissue critical to quality of life and cognitive health.
Original published by LT Wire.